Search Results 81-90 of 17255 for hba1c

1. Type 2 Diabetes Clinical Trials - Mayo Clinic Research

   The purpose of this study is to assess the effectiveness of Revita® DMR for improving HbA1c to ≤ 7% without the need of insulin in subjects with T2D ...

2. Safety And Feasibility Of Novel Therapy For Duodenal Mucosal Regeneration For Type II Diabetes (REGENT-1-US) - Mayo Clinic

   HbA1C of 7.5-10.0%, inclusive. BMI 24-40 kg/m^2, inclusive. On two to three non-insulin glucose lowering mediations, with one at maximum tolerated dose and ...

3. Pasireotide S.c. In Patients With Post-Bariatric Hypoglycaemia - Mayo Clinic

   - With an HbA1c at screening <6.5% - Not taking any medications for hyperglycaemia for at least 3 months prior to screening. - Their qualifying Level 3 ...

4. Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes - Mayo Clinic

   HbA1c ≥ 6.5%; Use of glucose-lowering agents. For female subjects: positive pregnancy test at the time of enrollment or study; History of prior upper ...

5. Dual-Hormone Control of Post-absorptive and Post-prandial Glucose in Type 1 Diabetes - Mayo Clinic

   HbA1c ≤ 10%; On insulin pump therapy for at least six months; no symptomatic gastroparesis; no unstable retinopathy (requiring photocoagulation within past 6 ...

6. Pioglitazone Versus Empagliflozin For Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus - Mayo Clinic

   * HbA1c level 7-10% at screening visit. * Fasting plasma glucose <220 mg/dL at screening visit. * Not on any antihyperglycemic medication except Metformin

7. Screening strategies for prevalent esophageal adenocarcinoma may be different from those recommended for Barrett's esophagus - Mayo Clinic

   HbA1c and alanine aminotransferase levels also were significantly higher in patients with BE compared with patients with EAC . Coronary artery disease was ...

8. Health and Wellness Coaching for Employees with T2D - Mayo Clinic

   an uninterrupted hemoglobin HbA1c ≥ 6.5% within a year despite standard care;; BMI of 25 or above (recorded or to be calculated) in the EMR;; have a T2D ...

9. Crossover Feasibility Study Of Portable AP Device With Zone-MPC And HMS And Adapted I:C And Basal Insulin - Mayo Clinic

   HbA1c ≤ to 10%, as measured with DCA2000 or equivalent device; Willing to perform the calibration of the study CGMs using a finger stick only and willing to ...

10. A Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment - Mayo Clinic

    HbA1c > 9.5% within 60 days before Day 1. Evidence of other forms of known chronic liver disease including: Positive test result at Screening for hepatitis ...